At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Mr Pascal Soriot performed for Shire in 2013.
2013 Liftstream Analysis: Mr Soriot commenced his new role in October 2012. He has been tasked with leading AstraZeneca through one of the most challenging periods in their history. Mr Soriot will shortly announce the long-term strategy he intends for AZ. This will no doubt include a strong desire to purchase outright or license-in products in 2013 ensuring the year is going to eventful for AstraZeneca as this new strategy take hold.
• Define new strategy and structure
• Convince investors his strategy works
• Align workforce to his new ideas and vision
• Acquire to fill pipeline and manage the effect of patent expiries
2014 Liftstream Verdict: 2013 saw Mr Soriot define the new structure quickly by moving AstraZeneca to Cambridge, UK to form a new global R&D headquarters closely in-line with their biologics franchise MedImmune. Mr Soriot began to make key acquisitions such as buying BMS’s share of the joint diabetes franchise, UK antibody company Spirogen and Pearl Therapeutics. In the past year AZ’s share price has steadily risen from 3,000p per share to 3,500p showing that investors are still confident in Mr Soriot’s plans. Mr Soriot’s first year in charge can be viewed as a relative success. On the whole, 2013 has been a positive transitional step for the company and the building blocks for potential future growth have been put in place. Will Mr Soriot continue implement his strategy in 2014, will AZ make a big acquisition in 2014?
To see how the other leaders profiled in Liftstream’s 13 for 2013 performed please click here. Liftstream would very much like to hear your thoughts on how you believe these life science leaders performed in 2013. Please leave your comments below, email email@example.com or tweet @liftstream #LSL13for13
Liftstream is an executive search and interim management recruitment company working exclusively within the global life sciences sector.